 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...345678910111213...2425» |
- |||||| Leukine (sargramostim) / Partner Therap
New P2b trial: Sargramostim Use in COVID-19 to Recover Patient Health (clinicaltrials.gov) - Jan 12, 2021
P2b, N=400, Not yet recruiting, Sponsor: Partner Therapeutics, Inc.
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
New P2 trial, Metastases: Sargramostim (GM-CSF) + PD-1 (clinicaltrials.gov) - Jan 10, 2021
P2, N=30, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date, Metastases: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Jan 6, 2021
P1, N=10, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial completion date: Dec 2020 --> Jan 2022
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Enrollment closed: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Jan 5, 2021
P3, N=813, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Dec 2020 --> Jan 2022 Recruiting --> Active, not recruiting
- | AST-302 / Aston Sci., EpiThany
Trial completion date, Trial primary completion date, Metastases: WOKVAC: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (clinicaltrials.gov) - Dec 28, 2020
P1, N=24, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Mar 2025 | Trial primary completion date: Dec 2020 --> Mar 2025
- |||| Leukine (sargramostim) / Partner Therap
Enrollment open: A Phase II/III Study of Sargramostim (clinicaltrials.gov) - Dec 27, 2020
P2/3, N=60, Recruiting, Sponsor: Nobelpharma
Trial completion date: Dec 2020 --> Mar 2025 | Trial primary completion date: Dec 2020 --> Mar 2025 Not yet recruiting --> Recruiting
- ||| Leukine (sargramostim) / Partner Therap
Enrollment change: iLeukPulm: Study of Sargramostim in Patients With COVID-19 (clinicaltrials.gov) - Dec 23, 2020
P2, N=120, Recruiting, Sponsor: Partner Therapeutics, Inc.
Not yet recruiting --> Recruiting N=60 --> 120
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open, Combination therapy: ANBL19P1: Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Dec 23, 2020
P2, N=45, Recruiting, Sponsor: Children's Oncology Group
N=60 --> 120 Not yet recruiting --> Recruiting
- | Unituxin (dinutuximab) / United Therapeutics
Journal: The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies. (Pubmed Central) - Dec 17, 2020
P2
For the 44 pts in first CR, 2-years rates for ASCT and non-ASCT patients were, respectively, EFS 65.5% vs. 58.7% (p = 0.48), and OS 71.4% vs. 85.4% (p = 0.63). In this retrospective, single center study, ASCT did not provide survival benefit when anti-GD2 immunotherapy was used after induction chemotherapy.
- | Leukine (sargramostim) / Partner Therap, FR Alpha Peptide Vaccine / National Cancer Institute
Trial completion date: Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer (clinicaltrials.gov) - Dec 16, 2020
P2, N=280, Recruiting, Sponsor: Academic and Community Cancer Research United
In this retrospective, single center study, ASCT did not provide survival benefit when anti-GD2 immunotherapy was used after induction chemotherapy. Trial completion date: Jul 2024 --> Jul 2026
- | Leukine (sargramostim) / Partner Therap
Enrollment closed, Trial completion date, Trial primary completion date: Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC) (clinicaltrials.gov) - Dec 9, 2020
P4, N=80, Active, not recruiting, Sponsor: University Hospital, Ghent
Trial completion date: Jul 2024 --> Jul 2026 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Oct 2020 --> Jan 2021
- | Leukine (sargramostim) / Partner Therap
Trial primary completion date: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) (clinicaltrials.gov) - Dec 8, 2020
P2, N=203, Active, not recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Oct 2020 --> Jan 2021 Trial primary completion date: Jun 2020 --> Dec 2020
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Dec 7, 2020
P2, N=64, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jun 2020 --> Dec 2020 Trial completion date: Oct 2020 --> Jan 2021
- || Leukine (sargramostim) / Sanofi, Ghent University Hospital, Tamiflu (oseltamivir) / Gilead, Roche
Clinical, Journal: Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy. (Pubmed Central) - Dec 1, 2020
Drug enrichment analysis of dysregulated genes has allowed us to propose novel therapies, including lung surfactants, respiratory stimulants, sargramostim, and oseltamivir. Our study presents a distinct mechanism of probable virus induced lung damage apart from cytokine storm.
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 30, 2020
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Our study presents a distinct mechanism of probable virus induced lung damage apart from cytokine storm. Trial primary completion date: Dec 2020 --> Mar 2021
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Trial primary completion date, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - Nov 25, 2020
P2, N=42, Active, not recruiting, Sponsor: Robin Kate Kelley
Trial primary completion date: Dec 2020 --> Mar 2021 Trial primary completion date: Dec 2021 --> Dec 2020
- |||||||| Leukine (sargramostim) / Partner Therap
New P2/3 trial: A Phase II/III Study of Sargramostim (clinicaltrials.gov) - Nov 23, 2020
P2/3, N=60, Not yet recruiting, Sponsor: Nobelpharma
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion date, BRCA Biomarker, PD(L)-1 Biomarker, Metastases: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov) - Nov 19, 2020
P1/2, N=90, Recruiting, Sponsor: Sellas Life Sciences Group
Trial primary completion date: Dec 2021 --> Dec 2020 Trial completion date: Jul 2021 --> Apr 2023
- | daunorubicin / Generic mfg.
Trial completion: Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia (clinicaltrials.gov) - Nov 17, 2020
P3, N=657, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial completion date: Jul 2021 --> Apr 2023 Active, not recruiting --> Completed
- || Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
Clinical, Review, Journal: Radioprotection and Radiomitigation: From the Bench to Clinical Practice. (Pubmed Central) - Nov 5, 2020
All FDA-approved radiation countermeasures (filgrastim, a recombinant DNA form of the naturally occurring granulocyte colony-stimulating factor, G-CSF; pegfilgrastim, a PEGylated form of the recombinant human G-CSF; sargramostim, a recombinant granulocyte macrophage colony-stimulating factor, GM-CSF) are classified as radiomitigators...Molecules under development with the aim of reaching clinical practice and other nonclinical applications are discussed. Assays to evaluate the biological effects of ionizing radiations are also analyzed.
- Zarzio (filgrastim biosimilar) / Novartis, Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche
[VIRTUAL] Real World Risk of Splenic Rupture with G-CSF/GM-CSF Therapy: A Pharmacovigilance Assessment Using FDA Adverse Event Reporting System (FAERS) Database () - Nov 5, 2020 - Abstract #ASH2020ASH_4931;
ROR was calculated separately for Pegfilgrastim 16.03 (95% CI 11.90-21.59), Filgrastim (49.79; 36.32-68.26), Lenograstim (133.82; 55.39-323.32), Filgrastim-sndz (87.87; 28.21-273.71), Filgrastim+Pegfilgrastim (35.01; 11.26-108.85), Filgrastim+Sargramostim (895.20; 214.83-3730.27) and for all G-CSF/GM-CSF drugs taken together (28.13; 22.92-34.52)...Conclusion This study demonstrates disproportionately elevated signals of developing splenic rupture in patient receiving G-CSF/GM-CSF therapy as compared to those receiving other drugs based on the FAERS database. Physicians should be aware of this rare adverse event as it could potentially lead to life-threatening outcomes.
- | Leukine (sargramostim) / Partner Therap, Danyelza (naxitamab) - Y / mAbs Therap
Trial completion date, Trial primary completion date: Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov) - Oct 22, 2020
P2, N=62, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Physicians should be aware of this rare adverse event as it could potentially lead to life-threatening outcomes. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment open: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Oct 19, 2020
P2, N=95, Recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Suspended --> Recruiting
- | Leukine (sargramostim) / Partner Therap
Biomarker, Enrollment open, Trial completion date, Trial primary completion date: Biomarker Assessments of Leukine During Treatment of Parkinson's Disease (clinicaltrials.gov) - Oct 19, 2020
P1, N=10, Recruiting, Sponsor: University of Nebraska
Suspended --> Recruiting Active, not recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Sep 2022
- sirolimus / Generic mfg.
[VIRTUAL] REFRACTORY SIROLIMUS-INDUCED PULMONARY ALVEOLAR PROTEINOSIS IN A PATIENT WITH LUNG TRANSPLANT () - Oct 12, 2020 - Abstract #CHEST2020CHEST_2617;
Sirolimus is implicated in drug induced PAP with expected reversibility when the medication is discontinued. This refractory case highlights the need for better understanding and treatment options in complex solid organ transplant patients.
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion date: Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (clinicaltrials.gov) - Oct 12, 2020
P1, N=66, Active, not recruiting, Sponsor: University of Washington
This refractory case highlights the need for better understanding and treatment options in complex solid organ transplant patients. Trial completion date: Dec 2023 --> Dec 2024
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 8, 2020
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2023 --> Dec 2024 Trial primary completion date: Sep 2020 --> Dec 2020
- | Leukine (sargramostim) / Partner Therap, MVI-816 / Madison Vaccines, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: NCI-2018-01474: pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer (clinicaltrials.gov) - Oct 7, 2020
P2, N=41, Recruiting, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Sep 2020 --> Dec 2020 Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2020 --> Oct 2022
- Leukine (sargramostim) / Sanofi, Ghent University Hospital
[VIRTUAL] A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neupeptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer () - Oct 2, 2020 - Abstract #SABCS2020SABCS_1112;
Background: GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with an FDA-approved immunoadjuvant Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF, Sargramostim, Leukine) that stimulates an immune response targeting HER2/neu expressing cancers...Accrual: The target enrollment is up to approximately 500 patients. Contact information: snehal.patel@greenwichlifesciences.com Funding: This trial is supported by Greenwich LifeSciences.
- | Leukine (sargramostim) / Partner Therap
Trial completion, Combination therapy: Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS (clinicaltrials.gov) - Oct 1, 2020
P2, N=26, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact information: snehal.patel@greenwichlifesciences.com Funding: This trial is supported by Greenwich LifeSciences. Active, not recruiting --> Completed
- ||| Leukine (sargramostim) / Sanofi, Ghent University Hospital, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Great news about the activation of the Phase 3 portion of EA6141 testing the triple combination of #ipilimumab #nivolumab & #sargramostim in advanced #melanoma @eaonc https://t.co/FGCp7qfouD (Twitter) - Sep 11, 2020
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap
Trial completion date, Trial primary completion date, Metastases: Pembrolizumab and GM-CSF in Biliary Cancer (clinicaltrials.gov) - Sep 11, 2020
P2, N=42, Active, not recruiting, Sponsor: Robin Kate Kelley
Active, not recruiting --> Completed Trial completion date: May 2021 --> Dec 2023 | Trial primary completion date: May 2020 --> Dec 2021
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed: NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Sep 9, 2020
P2, N=45, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2021 --> Dec 2023 | Trial primary completion date: May 2020 --> Dec 2021 Suspended --> Active, not recruiting
- | Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial completion date, Trial primary completion date, Checkpoint inhibition: Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov) - Sep 3, 2020
P1, N=10, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Suspended --> Active, not recruiting Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- Danyelza (naxitamab) - Y / mAbs Therap
[VIRTUAL] NAXITAMAB-BASED CHEMOIMMUNOTHERAPY FOR RESISTANT HIGH-RISK NEUROBLASTOMA: PRELIMINARY RESULTS OF HITS TREATMENT. (Hall 6) - Aug 26, 2020 - Abstract #SIOP2020SIOP_502;
P2
1-year Overall Survival is 55%, CI (39.4%, 76.9%). Conclusions High-dose naxitamab-based chemoimmunotherapy is safe and effective against chemoresistant HR-NB.
- ||| Leukine (sargramostim) / Partner Therap
Enrollment open, Trial primary completion date: iLeukPulm: Study of Sargramostim in Patients With COVID-19 (clinicaltrials.gov) - Aug 19, 2020
P2, N=60, Recruiting, Sponsor: Partner Therapeutics, Inc.
Conclusions High-dose naxitamab-based chemoimmunotherapy is safe and effective against chemoresistant HR-NB. Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2020 --> Jan 2021
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial suspension: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Aug 18, 2020
P2, N=95, Suspended, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2020 --> Jan 2021 Active, not recruiting --> Suspended
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Aug 17, 2020
P1/2, N=25, Completed, Sponsor: Yale University
Active, not recruiting --> Suspended Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Aug 10, 2020
P2/3, N=600, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Recruiting
- | Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial completion date, Combination therapy: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors (clinicaltrials.gov) - Aug 9, 2020
P1, N=6, Active, not recruiting, Sponsor: Mayo Clinic
Suspended --> Recruiting Trial completion date: Apr 2020 --> Jan 2025
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Enrollment open: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (clinicaltrials.gov) - Aug 8, 2020
P2, N=31, Recruiting, Sponsor: Virginia Commonwealth University
Trial completion date: Apr 2020 --> Jan 2025 Active, not recruiting --> Recruiting
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) - Aug 8, 2020
P2, N=95, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting Suspended --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial primary completion date, Metastases: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Aug 8, 2020
P1, N=10, Recruiting, Sponsor: Roswell Park Cancer Institute
Suspended --> Active, not recruiting Trial primary completion date: Jul 2020 --> Dec 2020
- Leukine (sargramostim) / Sanofi, Ghent University Hospital
[VIRTUAL] THE INNATE IMMUNE SYSTEM MODULATOR GM-CSF/SARGRAMOSTIM IS SAFE AND POTENTIALLY EFFICACIOUS IN PARTICIPANTS WITH MILD-TO- M O D E R A T E A L Z H E I M E R ’ S D I S E A S E () - Aug 7, 2020 - Abstract #CTAD2020CTAD_85;
P2
One measure of cognition (i.e., MMSE) and two plasma measures of neuronal damage (i.e., UCHL-1 and total Tau) showed improvement after three weeks (15 injections) of GM-CSF/sargramostim treatment compared to baseline and compared to placebo. These results indicate that GM-CSF/ sargramostim shows promise as a potentially safe treatment for AD and provides support for our Alzheimer’s Association “Part the Cloud”-funded trial with a longer, 24-week-long treatment period.
- | Leukine (sargramostim) / Partner Therap
Enrollment open, Post-transplantation: GM-CSF With Post-Transplant Cyclophosphamide (clinicaltrials.gov) - Aug 7, 2020
P2, N=38, Recruiting, Sponsor: Northside Hospital, Inc.
These results indicate that GM-CSF/ sargramostim shows promise as a potentially safe treatment for AD and provides support for our Alzheimer’s Association “Part the Cloud”-funded trial with a longer, 24-week-long treatment period. Not yet recruiting --> Recruiting
- | Leukine (sargramostim) / Sanofi, Ghent University Hospital
Review, Journal: Recombinant human granulocyte macrophage-colony stimulating factor expressed in yeast (sargramostim): A potential ally to combat serious infections. (Pubmed Central) - Aug 2, 2020
Tec Kinase BTK is known to influence the expression of GM-CSFRα and regulates downstream signaling pathways, suggesting a role for GM-CSF in maintenance of defense against fungal infections in immune competent hosts. Further examination of the potential mechanism(s) of action for naturally occurring GM-CSF and recombinant human GM-CSF (rhu-GM-CSF) expressed in yeast (sargramostim) are reviewed.
- Leukine (sargramostim) / Sanofi, Ghent University Hospital
[VIRTUAL] Double Blind Placebo Controlled Trial of Safety and Efficacy of GM-CSF/Sargramostim in Subjects with Mild-to-Moderate Alzheimers Disease () - Aug 2, 2020 - Abstract #AAIC2020AAIC_3339;
P2
Further examination of the potential mechanism(s) of action for naturally occurring GM-CSF and recombinant human GM-CSF (rhu-GM-CSF) expressed in yeast (sargramostim) are reviewed. These results indicate that GM-CSF/sargramostim shows promise as a potential treatment for AD and that our Alzheimers Association Part the Cloud-funded 24-week treatment trial is warranted.
- | Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: STING: NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (clinicaltrials.gov) - Jul 26, 2020
P1/2, N=31, Not yet recruiting, Sponsor: Nationwide Children's Hospital
These results indicate that GM-CSF/sargramostim shows promise as a potential treatment for AD and that our Alzheimers Association Part the Cloud-funded 24-week treatment trial is warranted. Trial completion date: Dec 2023 --> Dec 2024 | Initiation date: Jun 2020 --> Jan 2021 | Trial primary completion date: Dec 2022 --> Dec 2023
- | Keytruda (pembrolizumab) / Merck (MSD), Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date: NIPRA: A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. (clinicaltrials.gov) - Jul 22, 2020
P=N/A, N=27, Completed, Sponsor: Gary Onik MD
Trial completion date: Dec 2023 --> Dec 2024 | Initiation date: Jun 2020 --> Jan 2021 | Trial primary completion date: Dec 2022 --> Dec 2023 Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jun 2020
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial completion date: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jul 16, 2020
P2, N=64, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jun 2020 Trial completion date: May 2020 --> Oct 2020